Lobbying Activity Report

2301-19855

Organization: Novartis Pharmaceuticals Canada Inc.
Associated registration: 8870-2301-29
Lobbying Activity date: 2022-06-17
Arranged a meeting: Yes
Posted date: 2022-07-14

In-house lobbyists who participated in the lobbying activity: Geoffrey Squires
Senior Public Office Holders who were lobbied in this activity: Maureen O'Donnel, Associate Deputy Minister
Health System Innovation, Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Request a meeting to discuss innovative program pioneered by the NHS (England) to address cardiovascular disease risk factor mitigation through a collaborative program created to identify and treat patients high risk for CVD due to elevated cholesterol levels that does not meet current Clinical Guideline standards as published by the Canadian Cardiovascular Congress. Enacting such a program in BC will impact health system resource use caused by the downstream impact of Cardiovascular disease; heart attack, stroke, etc. Footnote1
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
  • Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
 Health, Hospitals, Senior Citizens Footnote1
 
Senior officer who filed this Lobbying Activity Report: Andrea Marazzi
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
 
  1. Footnote1  Indicates new information that was added through a Lobbying Activity Report.
Date Modified: